The dose response relationships for induction of micronuclei in bone marrow and for induction of lacZ mutations in liver, large intestine, and bone marrow were assessed in mice after treatment with ethyl methanesulfonate (EMS). The animals were treated orally at doses between 1.25 to 260 mg/kg for up to 28 days. Statistical analysis indicated that the dose response curves were well compatible with a thresholded relationship with apparent thresholds AE25 mg/kg/day. In contrast, no threshold was apparent for the induction of alkylation-adducts in proteins and DNA. An approximately linear dose dependency was observed, indicating that the macromolecular targets were alkylated proportionally to the given dose. It is concluded that the cells have the capacity to repair large amounts of EMS-induced alkylations, up to the threshold dose, virtually error free (i.e., without adding to the background burden of clastogenic/mutagenic events). Since the statistical power to deˆne the`true' shape of the dose response curve is much more limited for in vivo studies compared to in vitro experiments with e.g., a bacterial reverse mutation system we assessed the dose response relationship for EMS induced mutations at the his G46 locus in alkylation repair proˆcient (TA1535, ogt ＋ ) and deˆcient (YG7104, Dogt) bacteria using as many as 23 dose levels. Clear sublinearity was apparent for TA1535 while linearity was obvious for YG7104. Applying curveˆtting with a`hockeystick' model a threshold dose of about 750 mg/plate was determined for TA1535. With curveˆtting using a benchmark model (PROAST) we estimated the e‹ciency of error-free repair by the ogt system at the diŠerent EMS exposures. The likelihood of erroneous repair approaches 0 with decreasing EMS concentrations. Together with recent studies on other alkylating agents our data argue for a change of paradigm concerning risk assessment of the exposure to simple DNA-alkylating genotoxins.
Introduction
Mutations and/or clastogenic eŠects generally arise from exposure to a genotoxic (DNA-damaging) agent. The mutagenic/clastogenic alteration might occur directly (i.e., by mispairing); or might be related to erroneous or unsuccessful/incomplete repair of the induced DNA lesion. Traditionally, the dose-response relation for mutagenic eŠects has been thought to have no threshold; that is, even the most miniscule exposure carries aˆnite (non-zero) chance for eliciting the eŠect. Recently, several publications have provided convincing experimental evidence that simple alkylating agents, such as methyl methanesulfonate (MMS) and ethyl methanesulfonate (EMS), cause mutational events with a thresholded dose-response relationship (1) (2) (3) .
When considering possible mechanisms for a thresholded dose-response relationship, two distinctive possibilities, both involving saturation processes, come to mind: 1) a thresholded dose response can arise if a scavenging and/or detoxiˆcation mechanism fully prevents accessibility of the genotoxin to the DNA (and thus averts induction of damages) up to a certain dose level; 2) a thresholded dose response can arise if a repair mechanism is capable of removing all DNA damages practically error free up to a certain damage level-even if DNA damages are induced in dose proportional fashion. We have provided evidence that the latter mechanism is responsible for thresholds in the dose response of the induction of micronuclei and gene mutations in mice treated daily for 7 or 28 days with EMS. In the present article, we further augment our arguments by describing dose response curves for mutation induction in repair proˆcient and deˆcient bacteria. We show that chance for erroneous repair in the ogt-repair proˆcient cells appears to approach zero with decreasing concentration of EMS resulting in a (practical) thresholded of the dose response curve.
Our in vivo studies on EMS were triggered by the need to assess the possible mutagenic/carcinogenic risk of patients accidentally exposed to EMS after ingesting contaminated Viracept (Nelˆnavir mesylate) tablets for a period of up to three months (4) (5) (6) (7) (8) . EMS has long been known as a standard alkylating agent and is used as a positive control in many in vitro and in vivo genetic toxicity assays. Yet, existing in vitro and in vivo data did not permit a su‹ciently convincing risk assessment for the levels at which patients were exposed to EMS (maximal dose of 0.055 mg/kg/day). Therefore, the marketing authorisation holder of Viracept, F. HoŠmann-La Roche, conducted a series of non-clinical investigations (2, 6, 7, 9) to better quantify the risk for adverse eŠects in the exposed individuals. For direct acting, DNA-damaging genotoxins, such as EMS, it has been generally assumed that dose-response relations are linear-or at least non-thresholded-due to their stochastic, all-ornothing, mode of action (10) . By default, the formation of tumours, heritable birth defects, and teratogenic eŠects are also accepted to follow a linear dose relation for these genotoxins. However, the publication by Doak et al. (1) provided strong evidence for a thresholded dose-response relationship for in vitro induction of micronuclei and gene mutations by EMS. Based on this publication, our studies were aimed at obtaining reassuring evidence for the absence of (geno)toxicological adverse eŠects in the Viracept patients. Our studies provided strong evidence for a thresholded dose response regarding both clastogenic and mutagenic activities of EMS (11) . The threshold dose was observed to be AE25 mg/kg/day, orders of magnitude higher than the maximal patient dose (2, 11) . This observation also held true (7, 8) when the assessment was based on drug metabolism and pharmacokinetics parameters (AUC, Cmax). On this basis, it was concluded that the Viracept patients did not experience any additional toxicological adverse eŠects, which would be attributable to their exposure to EMS (8) . This argument was accepted by the authorities and the initially issued request for registries for birth defects and/or tumorigenic eŠects in putatively aŠected patients was retracted (4) .
In the present publication, we revisit the earlier studies focussing on the dose-response curves of protein and DNA adduct formation in comparison to the doseresponse curves of the clastogenic and mutagenic eŠects in the bone marrow of mice exposed to EMS. We further enhance on our argument that the thresholded dose response relations are due to error free repair by detailed analysis of the dose response curves for mutation induction in ogt-repair proˆcient and deˆcient strains of S. typhimurium. Bacterial studies on the model mutagen EMS have been published in the literature in large numbers. The type of DNA damages induced and their reversal and repair by a multitude of complex pathways have been described in great detail (12) (13) (14) (15) (16) (17) (18) (19) . Here we concentrate on curveˆtting and mathematical modelling of the dose response curves rather than on the discussion of detailed molecular processes.
Material and Methods
The experimental details of the MNT and Muta TM Mouse studies are described in Gocke et al. (2) (2) . CD2-lacZ80/HazfBR mice were obtained from Harlan, UK. The study consisted of two arms: a 28-day, daily treatment scheme (EMS: 0, 1.56, 3.13, 6.25, 12.5, 25, 50, 100 mg/kg/day, sampling on day 31) and a single treatment scheme (EMS: 0, 350 mg/kg, sampling on day 7 or day 31). Where possible, data were generated for at least 200,000 pfu per tissue for all 7 animals per group.
Protein adduct determination: Blood was obtained from each animal during necropsy by cardiac puncture and processed for analysis of ethylvaline levels. The determinations were made for all animals treated with EMS (2,6).
Bacterial reverse mutation (Ames test): The standard procedure for the Ames plate incorporation test was followed (20) . In addition to the standard tester strain TA1535 (ogt ＋ ) the repair deˆcient derivative YG7104 ( Dogt), kindly supplied by T. Nohmi, was employed (16) . 23 dose points (three plates/dose) spaced evenly by a factor of 1.22 were used in addition to 21 solvent control plates.
Statistical assessment: The statistical assessment of the in vivo genotoxicity data is described in detail in Gocke and Wall (11) . The threshold software developed by Lutz and Lutz (21) was employed to calculate the threshold dose values including conˆdence limits. For 
Results

In Vivo Studies with EMS
In the course of our studies (2) on the genotoxic activity of EMS, we investigated its clastogenic action in bone marrow and its mutagenic action in bone marrow, liver and large intestine.
In these studies, the induction of globin adducts in peripheral blood was also investigated as a measure of exposure in order to model pharmacokinetics (7) in the patients exposed to EMS-contaminated Viracept. In Fig. 1 the genotoxic eŠects and the adduct levels are plotted relative to their corresponding control values. It is apparent that low dose levels do not result in increases of the mutagenic/clastogenic eŠects but they do substantially increase the level of adducts. Indeed, for the clastogenicity endpoint, even a negative (hormesis-like) trend was apparent, which was assessed as being statistically signiˆcant (11) . Above the NOEL doses of 25 to 50 mg/kg/day for lacZ induction and 80 mg/kg/day for MN induction, clear increases of the genotoxic eŠects are observed, reaching a factor of 8.7 (MN) at dose 200 mg/kg/day or 4.0 (lacZ) at dose 100 mg/kg/day relative to the respective control values. Using the threshold software developed by Lutz and Lutz (21), we obtained estimates of the threshold values and conˆdence intervals. Figure 2 shows a representative`hockeystickmodelling' for lacZ mutations in bone marrow. Table 1 summarizes the data for all endpoints.
In contrast to the clastogenic and mutagenic eŠects, it is evident that no threshold for adduct formation can be derived from the data shown in Fig. 1 . In fact, an almost 10 fold increase over background is apparent already at the lowest dose of about 1 mg/kg/day. At the threshold doses for genotoxicity, the ethylvaline levels surpass the background values by a factor of about 1000. In our studies (2,6) we determined globin adducts as a measure of exposure in order to model pharmacokinetics of EMS in patients (7) . Previous investigations of Murthy et al. (23) determined adduct levels in DNA. Comparing these data to our results showed a high degree of parallelity for ethylation of both targets as depicted in Fig. 3 . Murthy et al. (23) used radioactive EMS, enabling them to obtain reliable data down to dose levels below 0.1 mg/kg of EMS because background ethylation does not interfere with the measurements. Figure 3 shows, at doses below 10 mg/kg, they observed a roughly linear dose relation (i.e., slopes in the log-log plot of about 1), and, at doses above 10 mg/kg, they observed a nearly quadratic relation (i.e., slope close to 2 in log-log plot). When calculating the daily increments of globin-adduct levels in our 7 or 28 day studies (2) , our values compare well with the data reported by Murthy et al. (23) .
In Vitro Study with EMS in S. typimurium
In order to deˆne more closely the impact of DNA repair on the dose response of mutation induction we decided to use the S. typhimurium system with strain TA1535, which is alkyltransferase proˆcient, and its derivative YG7104 (Dogt) which is deˆcient for the ogt methyltransferase system. The ogt system was previously shown to constitute the main repair pathway in S. typhimurium for ethylating agents like EMS (17) . Investigations on the dose response of EMS in various bacterial systems have been performed many years ago and are summarized by Matijasevic and Zeiger (24) .
It is immediately apparent that TA1535 is less sensitive to EMS mutagenicity by orders of magnitude. Not only the slope but also the shape of the dose response curves diŠers between the two strains. The revertant frequency curve of TA1535 shows a clear sublinearity while for YG7104 a linear increase is apparent at the low dose range (at higher doses the downward curvature is due to toxicity and lower counting e‹ciency of the image analysis system at high colony densities). Consequently, the Lutz and Lutz software does not reject linearity and does not identify a threshold for YG7104 (data not shown) but returns a value of 773 mg/plate as threshold dose for EMS in TA1535 (Fig. 5) . It is noted that due to the continuously increasing upward curvature the application of the hockeystick model is not appropriate for the whole dose range as it would result in an obvious overestimate of the td value (not shown). Therefore we limited the evaluated dose range in Fig. 5 to concentrations of up to 2500 mg/plate where the increase of the revertant frequency was not more than 10 fold over control.
In an alternative approach weˆtted the data with the PROAST software (22) using the exponential model (15) . Note: For YG7104 the leveling oŠ of the number of revertant colonies/plate at higher (À10 mg/plate) concentrations is mainly due to ine‹cient colony separation at high colony densities and start of toxicity. The extrapolation of the linearˆt in the low dose range (with the initial slope calculated in the text for YG7104) can be seen as representing the number of pro-mutagenic lesions induced in the absence of the ogt system. For induced revertants of TA1535 negative values (i.e., where colony number on treated plate was lower than on control plates) a value of 1*10 -4 was inserted as negative values cannot be plotted in log-log scale.
Thresholds for Alkylating Agents
The constants a, b, c, d deˆne background level, potency (`rapidity' of increase), maximum response, and shape of the curve (15) . Fitting the TA1535 and YG7104 data resulted in the following equations (rf＝revertant frequency, x＝concentration of EMS in mg/plate) rf1535＝11＊(1000-(1000-1)＊exp ×(-4.995＊10 -11 ＊x 2.5 )) and rf7104＝15.9＊(118-(118-1)＊exp (-0.04915＊x))
In Fig. 6 we show the frequency of revertant colonies, induced revertant colonies and theˆtted curves in a loglog plot. We estimate the repair e‹ciency by the ogt system as a function of the EMS concentration, as discussed below. The PROAST software calculates the concentration of 252 mg/plate as benchmark dose (＝estimate of dose increasing the colony numbers by 5z) for TA1535 while a roughly 30,000 fold lower benchmark dose (0.0087 ug/plate) is calculated for YG7104. It is notable that thê tting resulted in d＝1 for YG7104 and d＝2.5 for TA1535. This has decisive implications for the slope (i.e., theˆrst derivative):
At low concentrations the slope for YG7104 (with d＝1) approaches the value of 91.4
xª0rf? 7104ª91.4 revertants/ug of EMS and for TA1535 (with d＝2.5) the slope approaches 0 xª0rf? 1535ª0 revertants/ug of EMS. Consequently, this analysis agrees the assessment with the Lutz and Lutz (21)`hockeystick model' that a linear dose relationship is seen for YG7104 and a threshold can be seen for TA1535.
Discussion
EMS has been investigated in numerous in vitro and in vivo studies for the induction of gene mutations and clastogenic events (1, 12, 24, 26) . In vivo rodent studies employing doses of AE50 mg/kg/day were not amenable to the elucidation of dose-response relationships at lower doses, which was of particular relevance for assessing the genotoxic risk of the patients exposed to EMS-contaminated Viracept (4) . Graphical assessment of these published in vivo studies, as presented in Gocke et al. (26) , suggested sub-linear dose relations for almost all investigations. However, deˆnite conclusions from these studies could not be drawn because of experimental restrictions (e.g., lack of doses below the LOEL, too few animals in controls and treatment groups, and too few cells analysed per animal).
Our studies (2) were designed to give a reliable experimental and statistical basis for determination of a threshold dose, should it exist in vivo. Thus, we employed 7 to 8 closely spaced dose levels starting as low as 1.25 mg/kg/day, included several (up to 4) independent control groups, increased the number of animals/dose group and the number of evaluated cells/animal above the levels recommended in the respective guidelines. This approach provided 5 to 6 dose levels that were identiˆed to be below the LOEL dose.
Fixation of mutations likely depends on the status of proliferation and diŠerentiation of the exposed cells. Studies with short-term treatments indicated that the sensitivity of stems cells might be higher or lower than the sensitivity of transit or diŠerentiated cells, depending on the organ investigated (27) . In our Muta TM Mouse study, we included three organs (liver, intestine, bone marrow) with diŠerent turnover rates, and the treatment period of the study was chosen to be 28 days, so that the induction of lacZ mutations was measured in diŠeren-tiated, transit and stem cells in the diŠerent organs. We also included a single, acute treatment regiment to show that dose fractionation abolishes the mutagenic eŠect when the daily dose is below the threshold, while the acute dose, equal to the total cumulative dose, induces a clear increase (2) .
We believe our data provide unambiguous and reliable support for a thresholded dose-response relationship. When applied to human risk assessment, thè traditional' approach of linear back-extrapolation for DNA damaging genotoxins/carcinogens can be replaced by the application of appropriate safety factors (8) as has already been accepted for non-DNA damaging genotoxins.
While the dose response relations for genotoxic eŠects were assessed to follow a`hockey-stick' fashion, our data on globin ethylation, as well as the data of Murthy et al. (23) on the alkylation of N7-G ethylation, provide convincing evidence that induction of alkylation damage after EMS exposure does not occur in a threshold manner down to dose levels of 0.1 mg/kg (Figs. 1, 3 ). This implies that there is no e‹cient scavenging of EMS prior to reaction with DNA. As a consequence, the appearance of thresholds in the doseresponse curve for clastogenic and mutagenic eŠects has to be attributed to error-free removal of DNA damage. In a calculation described in Gocke and M äuller (28), we have derived that in liver cells treated at the NOEL dose of lacZ mutation induction (50 mg/kg/day) each daily EMS dose induced 380,000 DNA alkylations without any measurable increase in mutation frequency. For bone marrow cells, the calculation yields a total of 78,000 adducts at the NOEL of 25 mg/kg/day, assuming a similar adduct induction in bone marrow DNA as in liver DNA. The diŠerent adduct levels at the threshold doses in the two organs might be due to the diŠerent cell turnover (i.e., the liver cells have more time to repair) or could be attributed to diŠerent capacities of the repair systems in the two organs (29) .
Zair et al. (30, 31) have recently shown that the threshold for induction of micronuclei in vitro is critically impacted by the N-methylpurine DNA glycosylase (MPG)/base excision (BER) repair system known to play a pivotal role in N 7 -ethyl Guanine repair. Complete ablation of a clastogenic threshold dose-response was seen in MPG-deˆcient human lymphoblastoid cells. Numerous studies on impact of repair capacities on shape of dose response have been published for EMS in the more distant history of mutagenesis research, as reviewed by Matijasevic and Zeiger (24) . While induction of alkylations rises linearly with concentrations, the induction of mutations varied with the 2.13 and 4.20 power of exposure for uvr ＋ and uvrB strains, respectively. Surprisingly, the excision-repair deˆcient strain showed relatively higher mutation frequencies at low concentrations but was less mutagenized at higher concentrations than the uvrB strains. O 6 -Alkyl guanine is thought to be the most critical DNA lesion for induction of gene mutations because of its mispairing potential (1, 18, 19) . Direct removal of the adducts is provided by the alkyl transferase enzymes (13) (14) (15) (16) (17) . In order to investigate the impact of the alkyltransferase enzymes on mutation induction we turned to the S. typhimurium system where repair deˆcient strains ( Dogt, Dada) derivatives of the standard tester strain TA1535 have been generated by the group of T. Nohmi (17) . Detailed knowledge about DNA damage reversal by alkyltransferases, as well as about other repair systems for alkylation damage, has been accumulated in a multitude of studies (13) (14) (15) (16) (17) (18) (19) 29, 30, 32) . For our intention to deˆne dose response relations we speciˆcally wanted to compare the eŠects of the main alkylation repair system on the shape of the dose response curves in a system where the impact of statistical variation can be minimized. The bacterial S. typhimurium histidin reversion system seemed well suited. As shown in Fig. 4 , the revertant frequency increases linearly in strain YG7104 at low concentrations (up to about 8 mg/plate), while the curve for TA1535 shows a very pronounced sublinearity. Assessment by the hockeystick software derives a threshold value of 773 mg/plate for TA1535 but clearly no threshold for YG7104. With the PROAST software the curves werê tted as graphically presented in Fig. 6 . The linearˆt of induced revertants of YG7104 in the low dose range represents the number of EMS lesions erroneously repaired in absence of ogt alkyltransferase, while theˆt of induced revertants for TA1535 represents the number of EMS induced lesions erroneously repaired in presence of the ogt alkyltransferases. It follows that the diŠerence between the two values is representing the number of lesions successfully removed by the ogt system. To visualize the dose dependency of the ogt-repair we plotted in Fig. 7 the ratio of (induced revertants of TA1535)/(induced revertants of YG7104), which can be seen as corresponding to the likelihood of an EMS induced lesion to lead to mutation when ogt repair is active. Erroneous repair appears to approach zero at low concentrations (Fig. 7) . On a log-log plot the ratio appears as a straight line with a slope (＝exponent) of 1.5.
Inherently, the exact shape is largely in‰uenced by the curveˆtting model and the back-extrapolation to very low concentration levels will carry increasing uncertainty. However, the large numbers of dose levels and plates we have used in the present study increases the conˆ-dence of the curveˆt. Based on the used model it is concluded that only about 1 lesion in 10 8 is erroneously repaired at 1 mg/plate. At the high dose end it can be estimated that still only about 2 in 10 3 lesions are erroneously repaired at 5000 mg/plate.
Conclusion
Emerging evidence from studies using alkylating agents, such as EMS, provide conˆdence to the conclusion that repair proˆcient cells have the capacity to eliminate high levels of alkylation damage without apparent increase of genotoxic eŠects. It is only at doses above the (apparent) threshold that a notable increase of clastogenic and mutagenic eŠects becomes evident. Our investigation (2) and the study of Doak (1) the dose response of ethylnitrosourea (ENU) did not exhibit a threshold. Since ENU induces ethylation of DNA as does EMS-albeit with a diŠerent target speciˆcity-an absence of threshold for ENU appears di‹cult to rationalize. Therefore it was reassuring that reanalysis of the Doak et al. study (30, 31) and further studies focussing on lower dose levels (3,34) provided evidence for thresholds in vivo and in vitro. In contrast, the data on protein and DNA alkylation do not show a thresholded dose response (2, 23, 24) . As has been argued (35) , this endpoint can be used to assess the extent of exposure (`biomarker of exposure'), but cannot be used as a`biomarker of eŠect' i.e., to estimate the extent of heritable genotoxic consequences. Simple alkylation might be considered as a ubiquitous and easily repairable DNA damage for which error-free repair processes have been evolved early on in the history of life. Other, more complex DNA damages might not be repairable without errors, even at very low doses. Interestingly, however, a recent study on tumour induction in trout (36) exposed to the genotoxin dibenzo[a,l]pyrene, which induces a host of bulky adducts, has yielded strong evidence for a deˆnitely sub-linear dose response, despite a near linear induction of complex bulky DNA adducts down to very low doses. Similar conclusions have been drawn in a study with a‰atoxin as detailed in the presentation by G. Bailey (37) . It is evident that linear back extrapolation from TD10 (or TD50) doses to the`virtual safe' dose (VSD, the dose inducing 1 cancer in a million individuals) yields a value that would be`too low' by orders of magnitude compared to the estimate by appropriate non-linear curveˆtting.
While a general change of the paradigm for risk assessment has to await the accumulation of further data on genotoxins inducing a wide variety of DNA lesions, the current tenet of`linearity at low doses' for mutagenic/clastogenic eŠects induced by DNA damaging compounds' can be refuted at least for simple alkylating agents.
